These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2516013)

  • 1. Cost-effective validation of screening tests.
    Joseph KS
    Int J Epidemiol; 1989 Dec; 18(4):996-8. PubMed ID: 2516013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sample size for comparative standards].
    Silva Morelli H; Rodriguez Tobar J
    Odontol Chil; 1981; 29(125-126):43-7. PubMed ID: 6963610
    [No Abstract]   [Full Text] [Related]  

  • 3. Simple, direct drug susceptibility testing technique for diagnosis of drug-resistant tuberculosis in resource-poor settings.
    Kim CK; Joo YT; Lee EP; Park YK; Kim HJ; Kim SJ
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1212-6. PubMed ID: 23823178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of added value of diagnostic tests].
    Moons KG; van der Graaf Y
    Ned Tijdschr Geneeskd; 2000 Jun; 144(26):1256-61. PubMed ID: 10908955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation components in India's family planning programme.
    Sadashivaiah K
    Bull Gandhigram Inst Rural Health Fam Welf Trust; 1981 Dec; 16(4):11-33. PubMed ID: 12266853
    [No Abstract]   [Full Text] [Related]  

  • 6. [The quality of measurement methods and its statistical estimation].
    Läärä E; Aro S
    Duodecim; 1988; 104(1):40-52. PubMed ID: 3409823
    [No Abstract]   [Full Text] [Related]  

  • 7. Is introducing rapid culture into the diagnostic algorithm of smear-negative tuberculosis cost-effective?
    Yakhelef N; Audibert M; Varaine F; Chakaya J; Sitienei J; Huerga H; Bonnet M
    Int J Tuberc Lung Dis; 2014 May; 18(5):541-6. PubMed ID: 24903790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is gold standard and what is ground truth?
    Cardoso JR; Pereira LM; Iversen MD; Ramos AL
    Dental Press J Orthod; 2014; 19(5):27-30. PubMed ID: 25715714
    [No Abstract]   [Full Text] [Related]  

  • 9. How to avoid kernicterus.
    Newman TB; Maisels MJ
    J Pediatr; 2003 Feb; 142(2):212-3; author reply 214-5. PubMed ID: 12584551
    [No Abstract]   [Full Text] [Related]  

  • 10. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.
    ; Torlakovic EE; Riddell R; Banerjee D; El-Zimaity H; Pilavdzic D; Dawe P; Magliocco A; Barnes P; Berendt R; Cook D; Gilks B; Williams G; Perez-Ordonez B; Wehrli B; Swanson PE; Otis CN; Nielsen S; Vyberg M; Butany J
    Am J Clin Pathol; 2010 Mar; 133(3):354-65. PubMed ID: 20154273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of CI in developing countries.
    Magro I; Emmett SD; Saunders J
    Curr Opin Otolaryngol Head Neck Surg; 2018 Jun; 26(3):190-195. PubMed ID: 29528875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?
    Shahtaheri RA; Borhani Haghighi A; Safari A; Cruz-Flores S
    Int J Stroke; 2012 Oct; 7(7):E9. PubMed ID: 22989402
    [No Abstract]   [Full Text] [Related]  

  • 13. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.
    Leech AA; Kim DD; Cohen JT; Neumann PJ
    Value Health; 2018 Jul; 21(7):759-761. PubMed ID: 30005746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in Interpreting the Ob/Gyn Literature: Studies of Screening.
    Prabhu M; Riley LE
    Clin Obstet Gynecol; 2022 Jun; 65(2):244-251. PubMed ID: 35354158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of LED fluorescence microscopy in the diagnosis of pulmonary tuberculosis in Indian settings.
    Kelly V; Sagili KD; Satyanarayana S; Reza LW; Chadha SS; Wilson NC
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):696-701. PubMed ID: 25946362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis: developing nations left behind.
    Singer ME
    Pharmacoeconomics; 2008; 26(5):359-61. PubMed ID: 18429653
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
    de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
    Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.
    Glassman A; Cañón O; Silverman R
    Value Health; 2016 Dec; 19(8):913-920. PubMed ID: 27987640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of the GSK method to the determination of minimum sample sizes.
    Rochon J
    Biometrics; 1989 Mar; 45(1):193-205. PubMed ID: 2655729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effective use of investigations in developing countries.
    Malaviya AN; Kapoor S
    Best Pract Res Clin Rheumatol; 2014 Dec; 28(6):960-72. PubMed ID: 26096096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.